Comparing Innovation Spending: Opthea Limited and Xencor, Inc.

Biotech R&D: Opthea vs. Xencor's Innovation Race

__timestampOpthea LimitedXencor, Inc.
Wednesday, January 1, 2014340168518516000
Thursday, January 1, 2015428422834140000
Friday, January 1, 2016358129551872000
Sunday, January 1, 2017483830071772000
Monday, January 1, 20182489153497501000
Tuesday, January 1, 201931347891118590000
Wednesday, January 1, 202017480747169802000
Friday, January 1, 202134710152192507000
Saturday, January 1, 2022108459978199563000
Sunday, January 1, 2023181563523253598000
Monday, January 1, 2024176326321
Loading chart...

Unleashing the power of data

Innovation Spending: A Tale of Two Companies

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Opthea Limited and Xencor, Inc. have been at the forefront of this race since 2014. Over the past decade, Xencor has consistently outpaced Opthea, with its R&D expenses growing by over 1,270% from 2014 to 2023. Opthea, while trailing, has shown a remarkable increase of over 5,200% in the same period. Notably, in 2023, Xencor's R&D spending reached its peak, surpassing Opthea by approximately 40%. However, data for 2024 is incomplete, leaving room for speculation on future trends. This comparison highlights the dynamic nature of innovation investment in the biotech sector, where strategic spending can lead to groundbreaking advancements.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025